Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference 2026 in London

Rhea-AI Summary

Tiziana Life Sciences (Nasdaq: TLSA) will present a corporate overview and discuss intranasal foralumab trial results in London on November 18, 2026. CEO Ivor Elrifi will speak at the Jefferies Healthcare Conference at 14:30 GMT.

The Phase 2a INFORM-MS trial in non-active secondary progressive multiple sclerosis met its dual primary endpoints. The 50 μg dose reduced microglial activation, a measure of brain immune-cell activity, versus placebo on TSPO PET imaging (p=0.0168), with favorable safety and tolerability. Fatigue improvements were clinically meaningful and statistically significant on a secondary endpoint.

3 points · 1 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

How the balance works

Positive

• Major pointINFORM-MS met dual primary endpoints, including reduced microglial activation at 50 μg versus placebo (p=0.0168).
• Minor pointIntranasal foralumab showed a favorable safety and tolerability profile in the Phase 2a trial.
• Minor pointFatigue improvements were clinically meaningful and statistically significant on a secondary endpoint.

Negative

• None.

Key Figures

p-value: p=0.0168

p-value

p=0.0168

Phase 2a INFORM-MS; 50 μg intranasal foralumab versus placebo

Key Terms

tsPO PET imaging, monoclonal antibody, open-label, expanded access

4 terms

tsPO PET imaging medical

"as measured by TSPO PET imaging with the 50 μg dose"

TSPO PET imaging is a type of positron emission tomography scan that uses a radiolabeled ligand which binds the 18‑kDa translocator protein (TSPO) to map and quantify TSPO expression in tissues, most commonly the brain; TSPO levels rise in certain activated glial cells, so the PET signal is used as a biomarker of neuroinflammation or glial activation. The scan works by injecting a radioactive tracer that selectively binds TSPO, detecting emitted positrons to create images reflecting where and how much tracer is bound, and then quantifying uptake using measures such as standardized uptake values or kinetic modeling. Limitations include that TSPO expression is not uniquely specific to one cell type or to harmful inflammation, common genetic polymorphisms alter tracer binding affinity and must be accounted for, and accurate quantification often requires careful choice of tracer and modeling (sometimes arterial input), so signals need cautious interpretation.

monoclonal antibody medical

"a fully human anti-CD3 monoclonal antibody"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

open-label medical

"dosed in an open-label intermediate sized Expanded Access (EA) Program"

Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.

expanded access regulatory

"in an open-label intermediate sized Expanded Access (EA) Program"

Access that lets patients use an experimental drug or medical device outside of a formal clinical trial when no approved options are available. Think of it like allowing someone to test-drive a prototype car because they have no other transportation; for investors, expanded access can affect short-term demand, provide additional safety or usage information, and carry reputational or regulatory risks that may influence a company’s prospects and potential future sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announced that members of its senior leadership team will present at the Jefferies Healthcare Conference in London taking place from November 16-19, 2026.

The presentation will feature a corporate overview and discussion of the Company’s recent positive Phase 2a INFORM-MS topline results for intranasal foralumab in non-active secondary progressive multiple sclerosis (na-SPMS), following the Key Opinion Leader (KOL) call held on November 9, 2026.

Presentation Details
Event: Jefferies Healthcare Conference London
Date: Wednesday, November 18, 2026
Time: 14:30 GMT
Presenter: Ivor Elrifi, Chief Executive Officer

Management will also be available for one-on-one meetings throughout the conference. Interested parties may request meetings through the Jefferies conference portal or by contacting their Jefferies representative.

The recent Phase 2a INFORM-MS trial met its dual primary endpoints, including a statistically significant reduction in microglial activation as measured by TSPO PET imaging with the 50 μg dose of intranasal foralumab versus placebo (p=0.0168), along with a favorable safety and tolerability profile. Clinically meaningful and statistically significant improvements in fatigue were also observed in a secondary endpoint. These results were reviewed in detail during the Company’s KOL call with Tanuja Chitnis, M.D., principal investigator of the INFORM-MS trial, Tarun Singhal M.B.B.S, M.D., M.B.A., the Founding Director, NeuroPET Program Ann Romney Center for Neurologic Diseases, and Howard L. Weiner, M.D., Chairman of Tiziana’s Scientific Advisory Board, Robert L. Kroc Professor of Neurology, Harvard Medical School and Co-Director, Ann Romney Center for Neurologic Diseases, BWH.

A replay of the KOL call is available at: https://edge.media-server.com/mmc/p/7ox8odig

Additional materials and information are available in the Investors section of the Company’s website: https://ir.tizianalifesciences.com/investors

About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. Intranasal foralumab is also currently being studied in additional Phase 2 trials in AD, ALS, and MSA.

Intranasal foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.^[1],[2]

About Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative intranasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.

Forward-Looking Statements

Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These forward-looking statements reflect the current beliefs and expectations of Tiziana’s management and statements regarding completion of the INFORM-MS data analysis, presentation of detailed results, engagement with the FDA and potential further clinical development of intranasal foralumab. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Tiziana’s Annual Report on Form 20-F for the year ended December 31, 2025, and other periodic reports filed with the SEC from time to time. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

For further inquiries:

Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

[1] https://www.pnas.org/doi/10.1073/pnas.2220272120

[2] https://www.pnas.org/doi/10.1073/pnas.2309221120

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tiziana's Phase 2a INFORM-MS trial show?

INFORM-MS met its dual primary endpoints, including a statistically significant reduction in microglial activation with the 50 μg dose versus placebo (p=0.0168), alongside favorable safety and tolerability. Fatigue also improved on a secondary endpoint, with clinically meaningful and statistically significant results.